Former BMS executive charged in botched Plavix deal
25 April 2008
Eklavya Gupte, London
A former senior vice-president at Bristol-Myers Squibb has been charged by the US Department of Justice with lying to federal authorities over a deal struck with rival generics maker Apotex
According to the indictment, Andrew Bodnar – who left Bristol-Myers Squibb (BMS) in May last year – held a meeting with Canadian company Apotex in 2006 to discuss BMS’s plans to launch its own generic version of its blockbuster blood-thinning drug Plavix.
The Department of Justice says that at the meeting, Bodnar reassured Apotex that BMS would not launch a generic version of Plavix until 2011, when its patent was due to expire.
At the time of the meeting, the two companies were in litigation over...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial